Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.
Saved in:
| Title: | Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer. |
|---|---|
| Authors: | Piwarski SA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Howard LE; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA., Paul MA; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Bachelder N; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.; Biocore, Charlottesville, Virginia, USA., LaCroix B; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Clayton A; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.; Flatiron Health, New York, New York, USA., Allen D; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Kephart J; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Armstrong AJ; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Patierno SR; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., George DJ; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA., Hyslop T; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Freedman JA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA. |
| Source: | Cancer [Cancer] 2026 Jun 01; Vol. 132 (11), pp. e70371. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42186347 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Piwarski+SA%22">Piwarski SA</searchLink>; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Howard+LE%22">Howard LE</searchLink>; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Paul+MA%22">Paul MA</searchLink>; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Bachelder+N%22">Bachelder N</searchLink>; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.; Biocore, Charlottesville, Virginia, USA.<br /><searchLink fieldCode="AU" term="%22LaCroix+B%22">LaCroix B</searchLink>; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Clayton+A%22">Clayton A</searchLink>; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.; Flatiron Health, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Allen+D%22">Allen D</searchLink>; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Kephart+J%22">Kephart J</searchLink>; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Armstrong+AJ%22">Armstrong AJ</searchLink>; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Patierno+SR%22">Patierno SR</searchLink>; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22George+DJ%22">George DJ</searchLink>; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Hyslop+T%22">Hyslop T</searchLink>; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Freedman+JA%22">Freedman JA</searchLink>; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, North Carolina, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2026 Jun 01; Vol. 132 (11), pp. e70371. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42186347 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/cncr.70371 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e70371 Titles: – TitleFull: Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Piwarski SA – PersonEntity: Name: NameFull: Howard LE – PersonEntity: Name: NameFull: Paul MA – PersonEntity: Name: NameFull: Bachelder N – PersonEntity: Name: NameFull: LaCroix B – PersonEntity: Name: NameFull: Clayton A – PersonEntity: Name: NameFull: Allen D – PersonEntity: Name: NameFull: Kephart J – PersonEntity: Name: NameFull: Armstrong AJ – PersonEntity: Name: NameFull: Patierno SR – PersonEntity: Name: NameFull: George DJ – PersonEntity: Name: NameFull: Hyslop T – PersonEntity: Name: NameFull: Freedman JA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2026 Jun 01 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1097-0142 Numbering: – Type: volume Value: 132 – Type: issue Value: 11 Titles: – TitleFull: Cancer Type: main |
| ResultId | 1 |
